Aileron Therapeutics IPO

6/28/2017

IPO

$57,000,000

We currently estimate that we will use the net proceeds from this offering, together with our existing cash, cash equivalents and investments, as follows: approximately $7.0 million to fund our ongoing clinical trials of ALRN-6924, including approximately $1.0 million to fund our Phase 1 All-comers trial, approximately $3.0 million to fund our Phase 2a PTCL trial and approximately $3.0 million to fund our Phase 1/1b AML/MDS trials; approximately $30.0 million to $35.0 million to fund the potential expansion of our ongoing clinical trials of ALRN-6924, the initiation of additional clinical trials of ALRN-6924 by us or by clinical investigators, research related to ALRN-6924 and research related to our platform and other programs; and the remainder for working capital and other general corporate purposes, which may include funding for additional research, hiring additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

490 Arsenal Way
Watertown, MA 02472
USA

Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.